A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Many dietary nutrients are converted to active metabolites via enzymatic pathways. Beta-carotene is cleaved to retinol (vitamin A) by carotenoid oxygenase; conversion efficiency is ~12:1 (provitamin A equivalents). Tryptophan is converted to niacin (vitamin B3) via the kynurenine pathway with ~60:1 efficiency. Plant-based omega-3 ALA is converted to EPA and DHA via elongase and desaturase enzymes with very low efficiency (~5–10%). Genetic variants (single nucleotide polymorphisms, copy number variations) in biosynthetic enzymes alter conversion rates, explaining variable requirements and responses to supplementation. Bioconversion efficiency affects dietary adequacy and supplementation recommendations.
Calculate nutrient adequacy based on bioconversion rates and predicted intakes; compare bioavailability and bioconversion across nutrient forms and dietary sources.
Most people assume that eating a nutrient is the same as getting that nutrient — but the body often receives a raw ingredient and must manufacture the active form itself. This is the idea behind bioconversion: a dietary precursor (or provitamin) must pass through enzymatic steps before it can do biochemical work. You already know from vitamin activation that vitamins like B1 and B2 must be phosphorylated into coenzyme forms to participate in metabolism. Bioconversion extends that logic: sometimes the precursor in food isn't even the vitamin itself, but a chemically related compound that the body converts at varying efficiency.
The efficiency ratios are what make this clinically important. Beta-carotene, the orange pigment in carrots and sweet potatoes, is cleaved by carotenoid oxygenase in the intestinal wall into retinol (vitamin A). But the conversion is lossy: it takes roughly 12 micrograms of dietary beta-carotene to yield 1 microgram of retinol activity — a 12:1 ratio. This ratio worsens further when dietary fat is low, because beta-carotene absorption requires fat for micellar solubilization. The practical consequence: a person relying entirely on plant sources of vitamin A needs to eat substantially more than someone consuming preformed retinol from animal foods. Tryptophan-to-niacin conversion is even more inefficient at approximately 60:1, which explains why protein-poor diets (even if they contain some tryptophan) can lead to pellagra if niacin-rich foods are also absent.
The omega-3 conversion problem illustrates a different dimension: competing enzymatic demands. Alpha-linolenic acid (ALA), found in flaxseed and walnuts, is theoretically convertible to EPA and then DHA via elongase and desaturase enzymes. In practice, conversion rates are only 5–10% for EPA and far lower for DHA, because the same enzymes also process omega-6 fatty acids. When dietary omega-6 intake is high (as it is in most modern diets), the enzymes are largely occupied, leaving little capacity for ALA conversion. This is why preformed EPA and DHA from fatty fish or algae produce very different blood lipid responses than equivalent amounts of ALA.
The most important refinement to this picture is genetic variation. Single nucleotide polymorphisms (SNPs) and copy number variations in the genes encoding these biosynthetic enzymes — BCMO1 for beta-carotene cleavage, FADS1/FADS2 for fatty acid desaturation — create meaningful variation in conversion efficiency across individuals. Some people are efficient converters; others are "poor converters" who respond poorly to provitamin forms regardless of dietary intake. This is why nutrient recommendations increasingly distinguish between forms (retinol vs. beta-carotene; EPA/DHA vs. ALA) and why supplementation research must account for both the form used and the genetic background of study participants. Bioconversion efficiency, in short, means that two people eating the same diet may end up with very different effective nutrient intakes.
No topics depend on this one yet.